APC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_APC_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • 53-6dot7_APC_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100711 25 µg 27€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100712 100 µg 84€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Choi JG, et al. 2020. Front Immunol. 11:598556. PubMed
  2. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  3. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  4. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  5. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  6. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  7. Li X et al. 2019. Immunity. 50(3):576-590 . PubMed
  8. O'Malley G, et al. 2018. Cancer Immunol Res. 1.240277778. PubMed
  9. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  10. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  11. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  12. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  13. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  14. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  15. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  16. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  17. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  18. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  19. Zhao X, et al. 2022. Front Mol Biosci. 9:786864. PubMed
  20. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  21. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  22. Ma Z, et al. 2016. Clin Cancer Res. 22: 2969 - 2980. PubMed
  23. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  24. Leach SM, et al. 2020. Cell Rep. 33:108337. PubMed
  25. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  26. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  27. Dong L, et al. 2021. Cancer Cell. . PubMed
  28. Castiello MC, et al. 2020. J Allergy Clin Immunol. . PubMed
  29. Wang D, et al. 2018. Immunity. 48:659. PubMed
  30. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  31. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  32. Takeda Y, et al. 2018. Innate Immun. 24:323. PubMed
  33. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  34. Riley JS, et al. 2020. Blood Adv. 4:1102. PubMed
  35. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  36. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  37. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  38. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  39. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  40. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  41. Li ZX, et al. 2022. Arch Virol. :. PubMed
  42. Ghosh S, et al. 2022. APL Bioeng. 6:036105. PubMed
  43. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  44. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  45. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  46. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  47. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  48. Blumenthal D, et al. 2020. eLife. 9:e55995.. PubMed
  49. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  50. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  51. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  52. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  53. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  54. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  55. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
  56. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  57. Wagner V, et al. 2016. Sci Transl Med. 8: 366ra164. PubMed
  58. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  59. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  60. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  61. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  62. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  63. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  64. Lee JH, et al. 2018. Transgenic Res. 27:241. PubMed
  65. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  66. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  67. Yin Y, et al. 2021. ACS Nano. 15:14347. PubMed
  68. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  69. Zhan CS, et al. 2020. FASEB J. 14006:34. PubMed
  70. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  71. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  72. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  73. Eriksson E, et al. 2016. Gene Ther. 10.1038/gt.2016.80. PubMed
  74. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  75. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  76. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  77. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  78. Li Y, et al. 2019. Oncol Rep. 41:2679. PubMed
  79. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  80. Guo H, et al. 2022. PLoS Pathog. 18:e1010857. PubMed
  81. Frey N, et al. 2022. Nat Commun. 13:1804. PubMed
  82. Zhang J, et al. 2022. Front Immunol. 13:931740. PubMed
  83. Bhattacharya P, et al. 2022. PLoS Negl Trop Dis. 16:e0010224. PubMed
  84. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  85. Yin Q, et al. 2015. PLoS One. 10: 0137808. PubMed
  86. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  87. Matsumura K, et al. 2016. J Immunol. 197: 3233 - 3244. PubMed
  88. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  89. Solanki A, et al. 2018. Development. 145. PubMed
  90. Koliaraki V et al. 2019. Cell reports. 26(3):536-545 . PubMed
  91. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  92. Riffelmacher T et al. 2017. Immunity. 47(3):466-480 . PubMed
  93. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  94. Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed
  95. Si L, et al. 2022. Nat Biotechnol. 40:1370. PubMed
  96. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  97. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  98. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  99. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  100. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  101. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  102. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  103. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  104. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  105. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  106. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  107. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  108. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  109. Divan A, et al. 2018. PLoS One. 13:e0196893. PubMed
  110. He X, et al. 2021. Small. 17:e2007165. PubMed
  111. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  112. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  113. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  114. Jeong SH, et al. 2021. Nat Commun. 12:4405. PubMed
  115. Chen Q, et al. 2016. Nat Commun. 7:13193. PubMed
  116. Hoefflin R, et al. 2020. Nat Commun. 3.313194444. PubMed
  117. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  118. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  119. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  120. Zheng Z, et al. 2020. Cell Death Dis. 0.684722222. PubMed
  121. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  122. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  123. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  124. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  125. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  126. Yi X, et al. 2020. Sci Adv. 6:eaba3546. PubMed
  127. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  128. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  129. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  130. Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed
  131. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  132. Al–Zaher AA, et al. 2018. Mol Ther Oncolytics. 0.376388889. PubMed
  133. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  134. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  135. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  136. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  137. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  138. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  139. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
  140. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  141. Ye P, et al. 2022. Front Cardiovasc Med. 8:810477. PubMed
  142. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  143. Gibbins J, et al. 2014. Blood. 124:2953. PubMed
  144. Ku C, et al. 2015. Genes Dev. 29: 1930-1941. PubMed
  145. Cook KD, et al. 2015. Immunity. 43:703-714. PubMed
  146. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  147. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  148. Wanner-Seleznik GM, et al. 2020. Immunohorizons. 0.644444444. PubMed
  149. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  150. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  151. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  152. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  153. Matsuo K, et al. 2018. J Immunol. 200:800. PubMed
  154. Takaku S, et al. 2020. Integr Cancer Ther. 19:1534735419900798. PubMed
  155. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  156. Medyouf H, et al. 2010. Blood. 115:1175. PubMed
  157. Oka Y, et al. 2020. Sci Adv. 6:. PubMed
  158. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  159. Jiang Y, et al. 2020. Adv Mater. 32:e2001808. PubMed
  160. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  161. Li H, et al. 2021. Nat Commun. 12:7149. PubMed
  162. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  163. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  164. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  165. Zhang Q, et al. 2022. Nat Commun. 13:2406. PubMed
  166. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  167. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  168. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  169. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  170. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  171. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  172. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  173. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  174. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  175. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  176. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  177. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  178. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  179. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  180. Sun S, et al. 2013. J Immunol. 190:6209. PubMed
  181. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  182. Nanou A, et al. 2021. Cell Reports. 35(8):109168. PubMed
  183. Lin YH, et al. 2018. Cancer Immunol Res. 0.25. PubMed
  184. Morelli AE, et al. 2020. Cell Rep. 30:3448. PubMed
  185. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  186. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  187. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  188. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  189. Feng Y, et al. 2022. J Nanobiotechnology. 20:193. PubMed
  190. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  191. Alexandre YO, et al. 2020. Cell Reports. 33(13):108567. PubMed
  192. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  193. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  194. Wu L, et al. 2020. Cell Rep. 33:108327. PubMed
  195. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  196. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  197. Sasaki Y, et al. 2015. PLoS One. 10: 0131176. PubMed
  198. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  199. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  200. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  201. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  202. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  203. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  204. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  205. Frazer GL, et al. 2021. J Cell Biol. 220:. PubMed
  206. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  207. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  208. Kataru RP, et al. 2022. Front Aging. 3:864860. PubMed
  209. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  210. Huber MK, et al. 2021. J Vis Exp. :. PubMed
  211. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  212. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  213. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  214. Li X, et al. 2017. Front Immunol. 8:1186. PubMed
  215. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  216. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  217. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  218. Rao L, et al. 2020. Nat Commun. 11:4909. PubMed
  219. Murata T, et al. 2020. Sci Rep. 10:13560. PubMed
  220. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  221. Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed
  222. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  223. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  224. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  225. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  226. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  227. Lu C, et al. 2020. Cancer Cell. 39(1):96-108.e6. PubMed
  228. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  229. Zhang J, et al. 2018. Oncoimmunology. 7:e1461301. PubMed
  230. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  231. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  232. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
  233. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  234. Zheng Z, et al. 2021. Biomed Res Int. 2021:5535578. PubMed
  235. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  236. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  237. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  238. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  239. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  240. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  241. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  242. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  243. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  244. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  245. Liu YW, et al. 2022. JCI Insight. 7:. PubMed
  246. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  247. Chen B, et al. 2021. Cell. 184:6262. PubMed
  248. Smith LK, et al. 2021. Elife. 10:. PubMed
  249. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
  250. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  251. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  252. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  253. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  254. Cong L, et al. 2021. Breast Cancer Res. 23:51. PubMed
  255. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  256. Zhou P, et al. 2022. Mol Ther Oncolytics. 25:236. PubMed
  257. Zheng Y, et al. 2022. Transl Res. :. PubMed
  258. Funk KE, et al. 2021. Aging Cell. 20:e13412. PubMed
  259. Galeano Nio JL, et al. 2020. eLife. 9:00. PubMed
  260. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  261. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
  262. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  263. Bessell CA, et al. 2020. JCI Insight. 5:. PubMed
  264. Li C, et al. 2022. Front Cell Dev Biol. 10:913824. PubMed
  265. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  266. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
RRID
AB_312750 (BioLegend Cat. No. 100711)
AB_312751 (BioLegend Cat. No. 100712)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8a on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC, IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC, CyTOF®, IHC-F, IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC, 3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC, IHC-F, 3D IHC, SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC, IHC, SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC, CyTOF®, IHC, IP, Depletion, Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC, CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F, FC, 3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse CD8a

  • Biotin anti-mouse CD8a

  • FITC anti-mouse CD8a

  • PE anti-mouse CD8a

  • PE/Cyanine5 anti-mouse CD8a

  • Purified anti-mouse CD8a

  • PE/Cyanine7 anti-mouse CD8a

  • APC/Cyanine7 anti-mouse CD8a

  • Alexa Fluor® 488 anti-mouse CD8a

  • Alexa Fluor® 647 anti-mouse CD8a

  • Pacific Blue™ anti-mouse CD8a

  • Alexa Fluor® 700 anti-mouse CD8a

  • PerCP/Cyanine5.5 anti-mouse CD8a

  • PerCP anti-mouse CD8a

  • Brilliant Violet 421™ anti-mouse CD8a

  • Brilliant Violet 570™ anti-mouse CD8a

  • Brilliant Violet 650™ anti-mouse CD8a

  • Brilliant Violet 605™ anti-mouse CD8a

  • Ultra-LEAF™ Purified anti-mouse CD8a

  • Brilliant Violet 711™ anti-mouse CD8a

  • Brilliant Violet 785™ anti-mouse CD8a

  • Brilliant Violet 510™ anti-mouse CD8a

  • Purified anti-mouse CD8a (Maxpar® Ready)

  • Alexa Fluor® 594 anti-mouse CD8a

  • PE/Dazzle™ 594 anti-mouse CD8a

  • APC/Fire™ 750 anti-mouse CD8a

  • GoInVivo™ Purified anti-mouse CD8a

  • TotalSeq™-A0002 anti-mouse CD8a

  • Spark Blue™ 550 anti-mouse CD8a

  • Spark NIR™ 685 anti-mouse CD8a

  • TotalSeq™-C0002 anti-mouse CD8a

  • TotalSeq™-B0002 anti-mouse CD8a

  • Spark YG™ 570 anti-mouse CD8a

  • PE/Fire™ 640 anti-mouse CD8a

  • PE/Fire™ 700 anti-mouse CD8a

  • Spark Blue™ 574 anti-mouse CD8a Antibody

  • Spark Violet™ 423 anti-mouse CD8a Antibody

  • Spark UV™ 387 anti-mouse CD8a

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account